Patents by Inventor Joost Louwagie
Joost Louwagie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11970746Abstract: A method of processing a fecal sample from a human subject comprising combining a first portion of a collected fecal sample with a stabilizing buffer, combining a second portion of the sample with a solution that prevents denaturation or degradation of blood proteins found in a fecal sample. Embodiments comprise testing nucleic acid extracted from the first portion of the fecal sample for an amount of a human nucleic acid, and testing the second portion of the fecal sample for the presence of human blood.Type: GrantFiled: March 7, 2023Date of Patent: April 30, 2024Assignee: Exact Sciences CorporationInventor: Joost Louwagie
-
Patent number: 11845991Abstract: A method of processing a fecal sample from a human subject comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and detecting the presence of human blood in the removed portion of the fecal sample. The method further comprises stabilizing the remaining portion of the fecal sample.Type: GrantFiled: June 27, 2017Date of Patent: December 19, 2023Assignee: Exact Sciences CorporationInventor: Joost Louwagie
-
Publication number: 20230313317Abstract: A method of processing a fecal sample from a human subject comprising combining a first portion of a collected fecal sample with a stabilizing buffer, combining a second portion of the sample with a solution that prevents denaturation or degradation of blood proteins found in a fecal sample. Embodiments comprise testing nucleic acid extracted from the first portion of the fecal sample for an amount of a human nucleic acid, and testing the second portion of the fecal sample for the presence of human blood.Type: ApplicationFiled: March 7, 2023Publication date: October 5, 2023Inventor: Joost Louwagie
-
Publication number: 20230272488Abstract: A method of processing a fecal sample from a human subject comprising combining a first portion of a collected fecal sample with a stabilizing buffer that maintains DNA integrity in a fecal sample, and combining a second portion of the sample with a solution that prevents denaturation or degradation of blood proteins found in a fecal sample. Embodiments comprise testing DNA extracted from the first portion of the fecal sample for the presence of a human DNA, and testing the second portion of the fecal sample for the presence of human blood.Type: ApplicationFiled: March 7, 2023Publication date: August 31, 2023Inventor: Joost Louwagie
-
Patent number: 11634781Abstract: A method of processing a fecal sample from a human subject comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and detecting the presence of human blood in the removed portion of the fecal sample. The method further comprises stabilizing the remaining portion of the fecal sample.Type: GrantFiled: September 28, 2022Date of Patent: April 25, 2023Inventor: Joost Louwagie
-
Publication number: 20230048152Abstract: A method of processing a fecal sample from a human subject comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and detecting the presence of human blood in the removed portion of the fecal sample. The method further comprises stabilizing the remaining portion of the fecal sample.Type: ApplicationFiled: September 28, 2022Publication date: February 16, 2023Inventor: Joost Louwagie
-
Publication number: 20220064740Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: September 15, 2021Publication date: March 3, 2022Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 11149317Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: October 8, 2018Date of Patent: October 19, 2021Assignee: Exact Sciences Development Company, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 10808286Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: May 4, 2018Date of Patent: October 20, 2020Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Publication number: 20190276900Abstract: A method of processing a fecal sample from a human subject comprising removing a portion of a collected fecal sample and adding the removed portion of the sample to a buffer that prevents denaturation or degradation of blood proteins found in the sample, and detecting the presence of human blood in the removed portion of the fecal sample. The method further comprises stabilizing the remaining portion of the fecal sample.Type: ApplicationFiled: May 23, 2019Publication date: September 12, 2019Inventor: Joost Louwagie
-
Publication number: 20190032149Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: October 8, 2018Publication date: January 31, 2019Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Publication number: 20180327859Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: ApplicationFiled: May 4, 2018Publication date: November 15, 2018Inventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaetan Otto, Maarten Penning
-
Patent number: 9982308Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: February 4, 2015Date of Patent: May 29, 2018Assignee: EXACT SCIENCES DEVELOPMENT COMPANY, LLCInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Publication number: 20170298448Abstract: A method of detecting a predisposition to, or the incidence of, colorectal cancer in a fecal sample comprises, in a first step (a), detecting the presence of blood in the fecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer. The method additionally comprises, in second step (b), detecting an epigenetic modification in the DNA contained within the fecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer. Based upon a positive result obtained in either (a) or (b) or in both (a) and (b) a predisposition to, or the incidence of, colorectal cancer is detected. Related methods and kits involve detecting an epigenetic modification in a number of specific genes.Type: ApplicationFiled: June 27, 2017Publication date: October 19, 2017Inventor: Joost Louwagie
-
Patent number: 9388471Abstract: A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from FOXE1 and GATA4. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The sample comprises nucleic acid molecules from bladder cells. The methods may be used to select treatments and patients for treatment. Related kits include primers allowing the methylation status of the genes to be determined.Type: GrantFiled: March 11, 2010Date of Patent: July 12, 2016Assignee: MDxHealth SAInventor: Joost Louwagie
-
Publication number: 20160194723Abstract: A method of detecting a predisposition to, or the incidence of, colorectal cancer in a fecal sample comprises, in a first step (a), detecting the presence of blood in the fecal sample, wherein detection of the presence of blood is indicative of a predisposition to, or the incidence of, colorectal cancer. The method additionally comprises, in second step (b), detecting an epigenetic modification in the DNA contained within the fecal sample, wherein detection of the epigenetic modification is indicative of a predisposition to, or the incidence of, colorectal cancer. Based upon a positive result obtained in either (a) or (b) or in both (a) and (b) a predisposition to, or the incidence of, colorectal cancer is detected. Related methods and kits involve detecting an epigenetic modification in a number of specific genes.Type: ApplicationFiled: January 29, 2016Publication date: July 7, 2016Applicant: MDxHealth SAInventor: Joost Louwagie
-
Publication number: 20150240318Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, SOX17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging, or otherwise characterizing various diseases.Type: ApplicationFiled: February 4, 2015Publication date: August 27, 2015Applicant: MDxHealth SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Patent number: 8969046Abstract: A method of detecting a predisposition to, or the incidence of, cancer in a sample comprises detecting an epigenetic change in at least one gene selected from an NDRG4/NDRG2 subfamily gene, GATA4, OSMR, GATA5, SFRP1, ADAM23, JPH3, SFRP2, APC, MGMT, TFPI2, BNIP3, FOXE1, SYNE1, S0X17, PHACTR3 and JAM3, wherein detection of the epigenetic change is indicative of a predisposition to, or the incidence of, cancer. Also described are pharmacogenetic methods for determining suitable treatment regimens for cancer and methods for treating cancer patients, based around selection of the patients according to the methods of the invention. The present invention is also concerned with improved methods of collecting, processing and analyzing samples, in particular body fluid samples. These methods may be useful in diagnosing, staging or otherwise characterizing various diseases.Type: GrantFiled: January 9, 2008Date of Patent: March 3, 2015Assignee: MDxHealth SAInventors: Manon Van Engeland, Manon Adriaan De Bruine, Arjan Griffioen, Joost Louwagie, Katja Bierau, Gontran Brichard, Gaëtan Otto, Maarten Penning
-
Publication number: 20120027870Abstract: A method of detecting a predisposition to, or the incidence of, bladder cancer in a sample comprises detecting an epigenetic change in at least one gene selected from FOXE1 and GATA4. Detection of the epigenetic change is indicative of a predisposition to, or the incidence of, bladder cancer. The sample comprises nucleic acid molecules from bladder cells. The methods may be used to select treatments and patients for treatment. Related kits include primers allowing the methylation status of the genes to be determined.Type: ApplicationFiled: March 11, 2010Publication date: February 2, 2012Applicant: MSxHealth SAInventor: Joost Louwagie
-
Patent number: 7935490Abstract: The present invention relates to a solid phase immunoassay comprising on said solid phase an antigen in the presence of a reducing agent.Type: GrantFiled: August 2, 2006Date of Patent: May 3, 2011Assignee: N.V. InnogeneticsInventors: Geert Maertens, Joost Louwagie, Alfons Bosman, Erwin Sablon, Maan Zrein